Since they foot the bill for a lot of Americans’ healthcare costs, employers have a lot vested in the health of their populations and have been involved with pushing for healthcare transformation, said Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform.
Since they foot the bill for a lot of Americans’ healthcare costs, employers have a lot vested in the health of their populations and have been involved with pushing for healthcare transformation, said Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform.
Transcript
How are employers getting involved in the movement to value-based care? How have they been involved with healthcare transformation in the past?
Employers have a lot vested in the health of their populations, and even though it seems like they’re not a big player in the healthcare system, they actually foot the bill for a lot of Americans and benefit directly when their populations are healthy and productive and not distracted with dealing with the challenges of the healthcare system.
Employers have been involved with everything from pushing for standard ways to measure healthcare performance, public reporting on that performance, and now, tying payment to that performance, and even price and quality transparency writ large have been areas of interest to employers. So, they’re involved mostly through pushing their health plans to change the way that they are operating and the contracts that they have with providers.
But, also, some of them, especially the larger, more sophisticated ones have entered into direct contracts with providers and through those direct relationships have really been able to focus on quality, on efficient use of resources, and on getting more affordable care for their populations.
When employers look at new payment models and delivery models, is there anything that they think has the best potential?
I think employers want to see more bundled payment happen. The results have been, on the whole, promising, and there are some procedures and services that they buy over and over again for their population members that are unevenly prices and where there is uneven quality out in the market.
There have been examples of where, in working directly to providers and paying them with a bundled payment, employers have seen much more appropriate care delivered, where patients, who let’s say weren’t appropriate for having spine surgery, are now turned away by providers who have the right incentives to only focus on patients who need the care, and are paid in a way that enables them to do that.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More